Optiscan Imaging managing director and chief executive officer Dr Camile Farah said: “The potential benefits flowing from the InVue cannot be over-estimated. Diagnostic pathology is such a critical component in the surgical treatment of cancer, and for so long it has been disconnected from this process. InVue brings pathology and surgery together in the operating theatre to enhance the capabilities of both and ultimately facilitate faster and more accurate patient care.”

InVue is not Optiscan’s first foray into the medical imaging market. It plans to use a $3 million industry grant to further develop its gastrointestinal (GI) endomicroscope – and it says recent research suggests the device could generate an eye-watering $8 billion in additional market revenue in the US.

The Cooperative Research Centres Projects (CRC-P) grant from the Federal Government’s Department of Industry, Science and Resources will be directed towards the company’s second-generation project being led by its chief technology officer Dr Sanchitha Fernando.

Its patented imaging technology houses miniaturised componentry to create a pen-sized digital microscope that offers the power of real-time 3D single-cell imaging – all in the palm of a medical practitioner’s hand.

The company’s endomicroscopes are small, hand-held devices that can be touched against a sample of interest. Basically, they are fibre-optic fluorescence confocal microscopes that utilise a miniaturised optical fibre-scanning mechanism to generate an image.

Images are then generated by simply touching the probe against the tissue of interest.

Optiscan recently received a research-and-development tax incentive of $672,000 from the Australian Government and ended the last financial quarter with cash and equivalents of $7.12 million.

Its latest announcement also prompted a flurry of interest from the market, with its share price jumping more than 25 per cent on last week’s closing price of 11.5c to touch 14.5c today during intraday trading. Nearly five million of the company’s shares changed hands in the past two days.

With its latest imaging device officially launched and an important agreement with the world-renowned Mayo Clinic in place, Optiscan appears to be in good health as a company as it continues to build its impressive range of medical imagery technology.

Is your ASX-listed company doing something interesting? Contact: [email protected]